What do we know about nicotine pouches and oral health?

Which oral effects are most consistently reported?

Across the small clinical literature, the most repeated finding is a visible mucosal change at the habitual pouch-placement site. Reports describe white or wrinkled tissue, redness, soreness, dryness, blisters and irritation. The localization makes a mechanical or chemical contribution plausible, although formulation, previous snus use and oral hygiene can complicate attribution.

These findings do not all represent the same diagnosis or severity. A transient irritated area, hyperkeratosis, gingival recession and a biopsy-confirmed cellular change require different evidence and follow-up. Studies that combine them under “oral lesions” are useful for screening but cannot establish one uniform disease process.

How certain is the evidence?

Certainty remains low. The 2024 systematic review found only three eligible human studies involving 190 participants and judged all three at high risk of bias. Exposure histories were inconsistent, comparison groups were limited, and product strength, placement and concurrent cigarette, vape or snus use were not always controlled.

Newer studies add clinically examined participants but do not erase those limitations. Cross-sectional designs measure exposure and outcome at one point in time, making it difficult to establish what came first or separate pouch effects from prior behaviours. Longitudinal cohorts with repeated dental examinations are still needed.

What did the 2024 systematic review find?

The review searched major databases through February 2024 and included human observational or trial evidence reporting oral-health outcomes. Only three studies met its criteria, covering 190 participants in total. The reported effects included mucosal changes at placement sites, dry mouth, soreness, gingival blisters and other symptoms.

All included studies were judged to have a high risk of bias. Some relied on retrospective self-report, samples were small, and concurrent use of cigarettes, e-cigarettes or snus could not always be separated. The review therefore identified a recurring signal rather than a reliable incidence rate or causal estimate.

Its most important contribution is calibration. It supports asking clinicians and researchers to inspect the placement site and record symptoms, while showing that claims about long-term periodontal disease or cancer would outrun the available evidence. A systematic method does not create certainty when the underlying studies are sparse.

What does the newer Swedish clinical study add?

A 2026 cross-sectional study recruited people aged 18 to 30 from nine Swedish dental clinics: 126 nicotine-pouch users, 63 users of tobacco-derived oral pouches and 83 non-users. Dental professionals assessed mucosal responses and dental status, while participants reported use history and related behaviours.

Oral lesions were recorded in 79% of nicotine-pouch users and 89% of tobacco-derived pouch users. Redness and reported symptoms were more frequent among nicotine-pouch users, while hyperkeratosis was more prominent among the tobacco-derived group. The study did not find increased risk of caries or periodontal disease among participants with up to six years of use.

The result substantially enlarges the clinically examined evidence base, but it remains cross-sectional. Recruitment through dental clinics, a young age range, self-reported exposure and differences between user groups can affect estimates. “No increased risk observed” within this design and duration is not proof of no long-term effect.

What can histology and case reports tell us?

A 2024 case series selected five users with visible lesions for examination and biopsy. All had white changes at their placement sites. Histology described parakeratosis, epithelial thickening, oedema and chronic inflammatory cell infiltration. These observations show that some visible changes correspond to tissue-level alteration rather than colour alone.

Selection is the central limitation: researchers examined people with lesions, so the series cannot say how common such changes are among all users. It also cannot by itself isolate nicotine from pouch material, flavouring, pH, pressure, friction or previous product use. Its value lies in characterizing a phenomenon that larger studies can test.

Two later clinical case reports described localized recession, with leukoplakia in one case, at habitual placement sites. Alternative explanations were considered clinically, but histological confirmation was not obtained for the leukoplakia case. Case reports appropriately raise a signal; they do not convert temporal and anatomical association into a population risk estimate.

What is known about gum recession and periodontal disease?

Gingival recession means the gum margin has moved and exposed more of the tooth or root. Repeated pressure, local irritation, toothbrushing technique, thin tissue anatomy, inflammation and dental history can all contribute. A pouch placed in one location repeatedly creates a plausible site-specific mechanical and chemical exposure.

Current pouch evidence includes case reports and preliminary cross-sectional associations, but it does not establish an incidence rate, dose-response relationship or reversibility. The Swedish study’s failure to observe increased periodontal-disease risk within six years is reassuring only within its population and measurements; localized recession and generalized periodontal disease are not identical outcomes.

Longitudinal research should record exact placement, product, daily units, contact duration, nicotine content, pH, oral hygiene, smoking and prior snus use, then measure recession and periodontal indices repeatedly. Without that structure, an association can be exaggerated by confounding or hidden by grouping unlike exposures.

What is known about tooth decay and other dental outcomes?

Nicotine pouches do not expose teeth to smoke, but their effects cannot be inferred from that absence alone. Sweeteners, flavour systems, salivary changes, oral hygiene and patterns of concurrent product use may influence symptoms or dental outcomes. Product formulations differ and should not be treated as one uniform exposure.

The 2026 Swedish study reported no increased caries risk in users with up to six years of exposure. That is more informative than anecdote, yet the study was not a decades-long cohort and its young participants may have had limited time to develop some outcomes. It cannot rule out product-specific or longer-term effects.

Claims that pouches either cause cavities or protect teeth are therefore premature. Future studies need baseline dental status, validated caries measures, saliva and microbiome data, diet and hygiene variables, and follow-up long enough to separate pre-existing disease from new change.

What can be said about oral cancer?

There is not yet a pouch-specific longitudinal human evidence base capable of estimating oral-cancer risk. Modern products have not been used at scale for the decades usually required to observe and attribute rare chronic outcomes. Absence of demonstrated risk in this young literature is not proof that risk is zero.

A white lesion is not synonymous with cancer or a precancerous lesion. Frictional keratosis, inflammatory change and other benign conditions can appear white, while clinically similar lesions may require biopsy for diagnosis. That is why alarming images or isolated case reports should not be generalized, and why persistent changes should not be ignored.

Research should combine precise product chemistry and exposure histories with standardized clinical examination, biopsy where indicated and long follow-up. Until then, the defensible answer is that cancer risk is unknown rather than established or excluded.

What should users and dental professionals do with this evidence?

A person noticing a persistent patch, ulcer, lump, bleeding area, pain or recession should seek dental or clinical assessment rather than trying to diagnose it from a website. Moving a pouch does not establish that a lesion is harmless, and continuing to expose an affected site can complicate observation.

Dental histories should ask specifically about nicotine pouches, product name, strength, daily use, duration and placement. Recording photographs and site-specific findings over time can improve care and generate better surveillance data. Clinicians should distinguish advice for an existing nicotine user from any suggestion that a non-user initiate use.

The evidence also supports better product reporting. Studies and adverse-event systems need identifiers, ingredients, pH and use patterns. Retailers should not describe an entire category as “gum safe” or use the absence of tobacco leaf as proof that prolonged mucosal contact is harmless.